TapImmune, Inc. (TPIV) Starts Presentation at 2015 Marcum MicroCap Conference

TapImmune is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases. The company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally-processed epitopes designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. For more information, visit the company’s website at www.tapimmune.com.